沙利度胺联合VAD方案治疗多发性骨髓瘤临床观察被引量：1

导出

摘要目的:探讨多发性骨髓瘤(MM)沙利度胺联合VAD方案治疗的临床疗效。方法:选择26例多发性骨髓瘤患者,将其随机分成观察组和对照组各13例。观察组患者采用沙利度胺联合VAD方案治疗,对照组患者仅采用VAD方案治疗。观察比较两组患者的疗效及不良反应。结果:观察组总有效率为84.62,对照组总有效率为69.23%,观察组患者不良反应的单项发生率要明显高于对照组,差异均具有统计学意义(P<0.05)。结论:在治疗MM时,采用沙利度胺联合VAD方案,疗效满意,无严重不良反应,且价格不高,比较实用。

作者郑良宏

机构地区宝应县中医院

出处《亚太传统医药》 2013年第2期109-110,共2页 Asia-Pacific Traditional Medicine

关键词沙利度胺 VAD方案多发性骨髓瘤不良反应

分类号 R733.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1赵瑜,窦立萍,王书红,薄剑,王全顺,黄文荣,靖域,高春记,李红华,朱海燕,韩晓萍,于力.PAD与VAD两种方案对初治多发性骨髓瘤疗效和安全性比较[J].中华内科杂志,2010,49(9):762-764. 被引量：19
2屈敏,陈艳才.沙利度胺联合VMD方案治疗多发性骨髓瘤26例疗效观察[J].西部医学,2010,22(7):1210-1210. 被引量：2

二级参考文献12

1陈精予,刘昌发.沙立度胺联合化疗多发性骨髓瘤13例分析[J].中国误诊学杂志,2007,7(15):3646-3647. 被引量：2
2Dingli D,Nowakowski GS,Dispenzieri A,et al.Flow cytometric detection of circulating myeloma cells before stratification system in patients with multiple myeloma:a simple risk stratification system.Blood,2006,107:3384-3388.
3van de Velde H J,Liu X,Chen G,et al.Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.Haematologica,2007,92:1399-1406.
4Mehta J,Singhal S.High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.Bone Marrow Transplant,2007,40:1101-1114.
5Chaman-Khan A,Miller KC.Velcade,doxil and thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.Leuk Lymphoma,2005,46:1103-1104.
6Ciolli S,Leoni F,Giqli F,et al.Low dose velcade,thalidomide and dexamethasone (LD-VTD):an effective regimen for relapsed and refractory multiple myeloma patients.Leuk Lymphoma,2006,47:171-173.
7Richardson PG,Xie W,Mitsiades C,et al.Single-agent bortezomib in previously untreated multiple myeloma:efficacy,characterization of peripheral neuropathy,and molecular correlations with response and neuropathy.J Clin Oncol,2009,27:3518-3525.
8Berenson JR.Hematology:bortezomib in newly diagnosed multiple myeloma.Nat Rev Clin Oncol,2009,6:255-256.
9]Palumbo A,Rajkumar SV.Treatment of newly diagnosed myeloma.Leukemia,2009,23:449-456.
10O'Connor OA,Moskowitz C,Portlock C,et al.Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib:results of a multicentre phase 2 clinical trial.Br J Haematol,2009,145:34-39.